Or delivery systems that have one or more therapeutic agents with minimal toxicity t Urgently needed for patients. This problem to L Sen, the nanotechnology is used to produce one or more therapeutic DMXAA agents as a single drug evaluate its efficacy in clinical trials to encapsulate. Been developed are a number of delivery systems for the treatment of tumors nanotechnologies are polymeric nanoparticles, silicon and gold nanoshells, dendrimers, carbon nanostructures and liposomes. Nanotechnologies many have been shown to improve the circulation, improve the absorption of the drug in the tumor, avoidance of the reticuloendothelial system, and to reduce toxicity of t. Liposomes, the chemotherapeutic agent, siRNA, antisense ODN, DNA or radioactive particles that could target MAPK pathway, in various stages of development.
For example, liposomes with siRNA targeting AKT3 and V600EB RAF loaded synergistically inhibited melanoma tumor growth nozzles at M. Likewise ceramidecontaining liposomes in combination with sorafenib synergistically inhibited LY2940680 melanoma development in animals. Also demonstrated a phase I study that liposomal cisplatin drug delivery to enhance tumors, 200 times. Nanoparticles other than liposomes have been tested in animal models of melanoma. One of these studies showed that POLYD unique sechsz hnigen, L-lactic Coglycolic acid polymer chemically conjugated PD98059 inhibits the proliferation of melanoma cells, induced apoptosis in vitro and delayed Siege tumor growth in vivo. In addition, these nanoparticles have also been shown to enhance the anti-tumor activity of cisplatin.
Thus, nanoparticle delivery system technology load multiple drugs that may be genetically engineered in a vehicle and specific pharmacological, these means for the melanoma cells by conjugated Antique Rpern or peptides on the surface Surface. The use of RNAi technology MAPK target is always a viable option. siRNAs can k specifically inhibit target genes of the MAPK, the rapid reduction in animals but was big one obstacle it. Liposomes protect RNAi detected by RNases, and if with antique Rpern or specific ligands associated k Can particles loaded specifically in melanoma cells. Ver in a recently Ffentlichten report, called researchers from Alnylam Pharmaceuticals Inc.
and the Massachusetts Institute of Technology in 1200 b rsennotierte Barriers like other class of lipids lipidoids which are about 100 times more effective in delivering siRNA lipid barriers that previously reported basis . K Thanks to this technology You can a load of 3 to 30g/kg of siRNA against h Frequently used lipid levels periodically barriers that required at least 1 mg / kg for the gene silencing by more than 50%. The clinical efficacy of this approach to MAP kinase signaling pathways aimed to be proven. 7th Conclusions melanoma, specifically the MAPK pathway is a component of a therapeutic cocktail of drugs to treat this disease. The challenge is, the members of the optimal signaling cascade targets and drugs in biological negligible t Ssigbaren impact on toxicity Related site should be identified. Although the RAF or MEK Targeting B seems to be the best approach to the regulation of the combined inhibition of the key members of other signaling cascades mel